CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
6.56BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.6650xvs all stocks
52-Week Change
1177.96%vs all stocks
Market Capitalization
6.56BUSDvs all stocks (USD)
Enterprise Value
5.76BUSDvs all stocks (USD)
Forward P/E
-34.67xvs Biotechnology peers
Price to Book (MRQ)
15.14xvs Biotechnology peers
Enterprise to EBITDA
-44.11xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-17.92%vs Biotechnology peers
Return on Equity (TTM)
-69.86%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 18, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-130.68MUSDvs all stocks (USD)
Net Income (TTM)
-277.02MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-91.28MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-212.71MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-131.41MUSDvs all stocks (USD)
Pre-tax Income
-124.55MUSDFY2025 · Dec 31, 2025Net Income
-124.55MUSDFY2025 · Dec 31, 2025EBIT
-131.41MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-118.80MUSDFY2025 · Dec 31, 2025Research & Development
92.85MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
38.55MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
16.61MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-124.55MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-88.39MUSDFY2025 · Dec 31, 2025Free Cash Flow
-88.52MUSDDerived from operating cash flow minus capital expenditure. This filing charges 3.11M of depreciation against 128K of capital expenditure, and its own free-cash-flow line reads -105.08M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
74.21MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-124.55MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
3.11MUSDFY2025 · Dec 31, 2025Stock-based Compensation
24.90MUSDFY2025 · Dec 31, 2025Other Non-cash Items
9.50MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
513.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.86MUSDFY2025 · Dec 31, 2025Capital Expenditures
-128.00KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-9.50MUSDFY2025 · Dec 31, 2025Purchase of Investments
-150.97MUSDFY2025 · Dec 31, 2025Sale of Investments
261.03MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
109.92MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
310.81MSharesUpdated Jul 18, 2026Float Shares
207.89MSharesUpdated Jul 18, 2026Shares Short
32.32MSharesUpdated Jul 18, 2026Short Ratio
5.04daysvs all stocks
Short % of Shares Outstanding
11.66%vs all stocks
% Held by Insiders
9.69%vs all stocks
% Held by Institutions
85.08%vs all stocks
Total Cash (MRQ)
243.79MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.7840USDUpdated Jul 18, 2026Total Debt (MRQ)
45.95MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1168xvs Biotechnology peers
Current Ratio (MRQ)
9.52xvs Biotechnology peers
Book Value per Share (MRQ)
1.27USDUpdated Jul 18, 2026Total Assets
396.15MUSDvs all stocks (USD)
Total Current Assets
286.24MUSDFY2025 · Dec 31, 2025Total Liabilities
70.98MUSDFY2025 · Dec 31, 2025Total Non-current Assets
109.92MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
42.47MUSDFY2025 · Dec 31, 2025Total Current Liabilities
28.51MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
73.81MUSDFY2025 · Dec 31, 2025Other Short-term Investments
202.27MUSDFY2025 · Dec 31, 2025Accounts Payable
981.00KUSDFY2025 · Dec 31, 2025Short-term Debt
5.07MUSDFY2025 · Dec 31, 2025Long-term Debt
42.07MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
399.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
28.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-892.21MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
325.17MUSDvs all stocks (USD)
52-Week Low
1.33USDUpdated Jul 18, 202652-Week High
24.28USDUpdated Jul 18, 202652-Week Change
1177.96%vs all stocks
Beta
0.6650xvs all stocks
50-Day MA
14.31USDUpdated Jul 18, 2026200-Day MA
10.08USDUpdated Jul 18, 2026Avg 10-Day Volume
6.13MSharesUpdated Jul 18, 2026Avg 30-Day Volume
6.05MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-0.9300USDUpdated Jul 18, 2026Other Income / Expense
-9.75MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.56
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Market cap is $6.56B, above the global median of $1.15BNotable
Market cap (USD): 6,564,059,395Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Glenmark Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Xenon Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ptc Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Getinge AB
Tier 1ProductionApproval-Gated PipelineRuleFlow
Cogent Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
H. Lundbeck A/S
Tier 1ProductionApproval-Gated PipelineRuleFlow
Samsung Epis Holdings Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sunshine Guojian Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
CG Oncology, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Scholar Rock Holding Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Relay Therapeutics Inc.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Iovance Biotherapeutics, Inc.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
DigitalBridge Group Inc.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity